Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

3.800 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 306,789
Open 3.720
Bid (Size) 3.710 (300)
Ask (Size) 3.880 (1,200)
Prev. Close 3.800
Today's Range 3.600 - 3.840
52wk Range 1.900 - 4.650
Shares Outstanding 9,362,444
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Vistagen (VTGN) Q2 2026 Earnings Call Transcript ↗
Vistagen (VTGN) Q2 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update
From Vistagen
Via Business Wire

Performance

YTD
+14.6%
+14.6%
1 Month
-5.2%
-5.2%
3 Month
+28.6%
+28.6%
6 Month
+65.2%
+65.2%
1 Year
+34.8%
+34.8%

More News

Read More
News headline image
Earnings Scheduled For November 13, 2025 ↗
Via Benzinga
News headline image
Examining the Future: VistaGen Therapeutics's Earnings Outlook ↗
Via Benzinga
News headline image
Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025
From Vistagen
Via Business Wire
News headline image
Earnings Scheduled For August 7, 2025 ↗
Via Benzinga
News headline image
Insights into VistaGen Therapeutics's Upcoming Earnings ↗
Via Benzinga
News headline image
Vistagen to Participate in Stifel Healthcare Conference 2025
From Vistagen
Via Business Wire
News headline image
Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
News headline image
Vistagen Appoints Paul Edick to its Board of Directors
From Vistagen
Via Business Wire
News headline image
Vistagen to Present at The Menopause Society 2025 Annual Meeting
From Vistagen
Via Business Wire
News headline image
Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
From Vistagen
Via Business Wire
News headline image
Vistagen (VTGN) Q1 R&D Expense Jumps 54% ↗
Via The Motley Fool
News headline image
Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update
From Vistagen
Via Business Wire
News headline image
Insights Ahead: VistaGen Therapeutics's Quarterly Earnings ↗
Via Benzinga
News headline image
Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025
From Vistagen
Via Business Wire
News headline image
Vistagen to Present at the BTIG Virtual Biotechnology Conference
From Vistagen
Via Business Wire
News headline image
Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership
From Vistagen
Via Business Wire
News headline image
Vistagen Appoints Elissa Cote as Chief Corporate Development Officer
From Vistagen
Via Business Wire
News headline image
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
From Vistagen
Via Business Wire
News headline image
Earnings Scheduled For June 17, 2025 ↗
Via Benzinga
News headline image
Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025
From Vistagen
Via Business Wire
News headline image
Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year
From Vistagen
Via Business Wire
News headline image
Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York
From Vistagen
Via Business Wire
News headline image
Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference
From Vistagen
Via Business Wire

Frequently Asked Questions

Is Vistagen Therapeutics, Inc. - Common Stock publicly traded?
Yes, Vistagen Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Vistagen Therapeutics, Inc. - Common Stock trade on?
Vistagen Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vistagen Therapeutics, Inc. - Common Stock?
The ticker symbol for Vistagen Therapeutics, Inc. - Common Stock is VTGN on the Nasdaq Stock Market
What is the current price of Vistagen Therapeutics, Inc. - Common Stock?
The current price of Vistagen Therapeutics, Inc. - Common Stock is 3.800
When was Vistagen Therapeutics, Inc. - Common Stock last traded?
The last trade of Vistagen Therapeutics, Inc. - Common Stock was at 11/14/25 04:00 PM ET
What is the market capitalization of Vistagen Therapeutics, Inc. - Common Stock?
The market capitalization of Vistagen Therapeutics, Inc. - Common Stock is 35.58M
How many shares of Vistagen Therapeutics, Inc. - Common Stock are outstanding?
Vistagen Therapeutics, Inc. - Common Stock has 36M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.